ライフサイエンスコーパス: proangiogenic

1 Aspirin inhibits the production of proangiogenic 15(S)-HETE by platelet cyclooxygenase-1.

2 thus providing mechanistic insight into its proangiogenic actions in vitro and in vivo.

3 racellular matrix, promoting EC adhesion and proangiogenic activation by engaging alpha(v)beta(3).

4 ly weakly integrin-dependent EC adhesion and proangiogenic activation by fibronectin.

5 The circRNA cZNF292 exhibits proangiogenic activities in vitro.

6 uted tomography and histology, corroborating proangiogenic activities of M2-polarized liver macrophag

7 sis via proproliferative, antiapoptotic, and proangiogenic activities.

8 Proangiogenic activity during adipose tissue expansion i

9 g antibodies removed the CA-STAT5A-dependent proangiogenic activity from the conditioned medium of EC

10 g antibodies removed the CA-STAT5A-dependent proangiogenic activity from the conditioned medium of EC

11 addition to neuropilin-1, play a role in the proangiogenic activity of CgA(1-373).

12 The proangiogenic activity of the CgA(1-373) was blocked by

13 s antiangiogenic activity in contrast to the proangiogenic activity of VEGF-A.

14 tion of this regulatory axis next showed the proangiogenic activity of ZO-1 in both ex vivo and in vi

15 In vitro, FGD6 could regulate proangiogenic activity, and oxidized phospholipids incre

16 ing the C-terminal region) endowed of potent proangiogenic activity.

17 373 of human CgA(1-373), a fragment that has proangiogenic activity.

18 nses, phagocytosis, chemokine secretion, and proangiogenic activity.

19 26 is shown to free at least one target, the proangiogenic adrenomedullin, from repression, enhancing

20 ycemia-induced retinopathy wherein extensive proangiogenic alterations in blood vessel morphology and

21 , tumor necrosis factor (TNF), can have both proangiogenic and antiangiogenic effects, depending on t

22 clinical studies have assessed the impact of proangiogenic and antiangiogenic factors on endothelial

23 IL-8, tumor necrosis factor (TNF)-alpha, the proangiogenic and antiapoptotic enzyme cyclooxygenase-2,

24 iPSC-CMs could release significant levels of proangiogenic and antiapoptotic factors in the ischemic

25 ressiveness and poor prognosis by triggering proangiogenic and antiapoptotic signaling.

26 ation sites along with a lower expression of proangiogenic and antiinflammatory markers were also obs

27 Vs were enriched in miRNAs and proteins with proangiogenic and cytoprotective properties.

28 reased expression of genes associated with a proangiogenic and immunoinhibitory phenotype.

29 CSF-2 and CSF-3 confer proangiogenic and immunomodulatory properties to mesench

30 d as compelling candidates due to beneficial proangiogenic and immunosuppressive function.

31 MSCs drive monocyte differentiation toward a proangiogenic and lipopolysaccharide-unresponsive phenot

32 Exosomes can be proangiogenic and may have cardioprotective properties.

33 Fibroblast growth factors (FGF) act as proangiogenic and mitogenic cytokines in multiple myelom

34 Nintedanib targets proangiogenic and pro-fibrotic pathways mediated by the

35 he miR-155/CCN1 regulatory axis balances the proangiogenic and proinflammatory activities of microgli

36 ) induces a transcriptional induction of the proangiogenic and proinflammatory cytokine angiopoietin-

37 tes tumor angiogenesis through repression of proangiogenic and proinflammatory cytokines.

38 ethyl)pyrrole (CEP), which was shown to have proangiogenic and proinflammatory functions.

39 Angiopoietin-2 (Ang2) is a proangiogenic and proinflammatory vascular destabilizer

40 This proangiogenic and prolymphangiogenic microenvironment is

41 ltiple deleterious roles in cancer and exert proangiogenic and prosurvival activities.

42 LNA-92a exerts cell-protective, proangiogenic, and anti-inflammatory effects.

43 ammatory M1 as opposed to anti-inflammatory, proangiogenic, and tissue repair M2 phenotype, which may

44 thus contributing to the immunosuppressive, proangiogenic, and tumor-promoting effects of this pleio

45 Together, these initial data identify proangiogenic apelin as a key mediator of coronary vascu

46 Here we investigate the roles of the proangiogenic apelin receptor APLNR and its cognate liga

47 of fragments lacking the C-terminal region (proangiogenic) are present in circulation in healthy sub

48 t and this modification is important for its proangiogenic bioactivity.

49 nitoring to show that the host response to a proangiogenic biomaterial can be drastically affected by

50 ctional changes, endowing them with enhanced proangiogenic capabilities and, importantly, with a mark

51 itioning CSCs in high glucose attenuated the proangiogenic capacity of CSCs.

52 ased expression of glyoxalase-1 restored the proangiogenic capacity of diabetic CSCs, suggesting a me

53 mall (albeit not significant) shift toward a proangiogenic CD206(+)MHCII(-)(M2-like) macrophage respo

54 IIa) elicits TF cytoplasmic domain-dependent proangiogenic cell signaling independent of the alternat

55 approach to improve therapeutic efficacy of proangiogenic cells for the treatment of ischemic diseas

56 Expression of the proinflammatory and proangiogenic chemokine IL-8, which is regulated at the

57 deletion had no effect on the expression of proangiogenic chemokine or vascular endothelial growth f

58 results in elevated systemic levels of this proangiogenic chemokine that raises concerns for tumorig

59 In the adult, the role of developmental proangiogenic cues in repair of the established vasculat

60 Vascular endothelial cells respond to proangiogenic cues in the embryo by differentiation to s

61 The complex interplay of proinflammatory and proangiogenic cues is only partially understood.

62 This inflammatory signature included several proangiogenic CXCR2 receptor ligands.

63 ow that KIT D816V promotes expression of the proangiogenic cytokine CCL2 in neoplastic mast cells.

64 thelial growth factor A (VEGF-A) is a potent proangiogenic cytokine elevated in patients with periphe

65 inhibiting TF-FVIIa signaling that leads to proangiogenic cytokine expression and tumor cell migrati

66 For example, VEGF, a major proangiogenic cytokine induced by hypoxia, plays a criti

67 Semaphorin 4D (Sema4D) is a proangiogenic cytokine produced by several malignancies,

68 portant for VEGF, bFGF, EGF, IL-6, and other proangiogenic cytokine secretion in stromal and tumor ce

69 ect tumoral effects and through reduction of proangiogenic cytokine secretion via the microenvironmen

70 vascular endothelial growth factor (VEGF), a proangiogenic cytokine.

71 ophages into the laser lesions and increases proangiogenic cytokines promoting CNV.

72 ic cells (cDC), cDC1 and cDC2, that secreted proangiogenic cytokines.

73 hosphorylation required for the induction of proangiogenic cytokines.

74 The proangiogenic effect of CNP/NPR-C is dependent on activa

75 Midkine (MDK) might mediate the proangiogenic effect of intermittent hypoxia (IH) in pat

76 nockdown in vitro and may play a role in the proangiogenic effect of MEF2C knockdown on retinal EC tu

77 we demonstrated a paracrine promigratory and proangiogenic effect of miR-143-3p-enriched exosomes fro

78 To enhance the hypoxia-induced proangiogenic effect, CSCs were transfected with hypoxia

79 receptor 2 in ECs and largely mediated their proangiogenic effect.

80 function independently of its CNV-promoting proangiogenic effect.

81 ngosine-1-phosphate also seemed to exert its proangiogenic effects by stimulating directional filopod

82 s and their supernatants exerted more potent proangiogenic effects compared with CD34(-) PBMC subsets

83 clude that NT exerts its proinflammatory and proangiogenic effects during acute colitis via a NTR1-pr

84 To test whether the proangiogenic effects of B act via activation of VEGF pa

85 alization of BMP receptors and abrogates the proangiogenic effects of BMP signaling in endothelial ce

86 vel molecular mechanism underlying increased proangiogenic effects of CD34(+) PBMCs, that is, angiomi

87 resulted in significant loss or increase of proangiogenic effects of CD34(+) PBMCs.

88 f ADAM10/17 or knockdown of DLL4 reduced the proangiogenic effects of fibulin-3 in culture.

89 These proangiogenic effects were absent when platelets were tr

90 an important mediator with inflammatory and proangiogenic effects, in human gingival fibroblasts (HG

91 latelet cyclooxygenase-1 product with strong proangiogenic effects.

92 tion of their release impaired CD34(+) PBMCs proangiogenic effects.

93 es provides a novel pathway causing impaired proangiogenic effects.

94 nce that soluble CEA is sufficient to induce proangiogenic endothelial cell behaviors, including adhe

95 ation of MMPs, has the ability to generate a proangiogenic environment by altering the balance betwee

96 udy, we show that targeting the formation of proangiogenic epoxyeicosatrienoic acids (EET) by the cyt

97 evalent in many human cancers and can elicit proangiogenic expression in several cell types, but thei

98 In addition, KHSRP promoted a proangiogenic extracellular environment by regulating th

99 confirm that the peptide is indeed a strong proangiogenic factor and induces sprouting in cellular a

100 ls of the fibrovascular scaffold express the proangiogenic factor IL-1beta strongly, whereas retinal

101 The results from this study suggest that the proangiogenic factor MMP9 may play a role as a biomarker

102 for the induction of Ephrin-B2, an essential proangiogenic factor that drives endothelial cell tubule

103 r cells by the upregulated expression of the proangiogenic factor VEGF-A and by increased tumor angio

104 share some transcriptional targets, like the proangiogenic factor VEGFA.

105 Furthermore, we find that VEGF, a potent proangiogenic factor, is induced by activation of STAT5A

106 othelial growth factor A (VEGF) is a crucial proangiogenic factor, which regulates blood vessel suppl

107 genes belonging to the following categories: proangiogenic factors (MMP9, VEGFA), chemokines (CXCL1,

108 ble change in the level of IL-1beta or other proangiogenic factors analyzed.

109 ntrol the balance between antiangiogenic and proangiogenic factors and initiate the angiogenic switch

110 nce of this recruitment is the generation of proangiogenic factors and matrix metalloproteinase prote

111 endothelial cells to produce VEGF and other proangiogenic factors and provide the inflammatory micro

112 Notably, blockade of proangiogenic factors in combination with stimulation of

113 anscriptome analysis confirmed activation of proangiogenic factors in hypoxic HSC.

114 s to target IL-6 and TNF-alpha as additional proangiogenic factors in the cornea during the developme

115 e myeloid cells are known to secrete several proangiogenic factors in tumors, including IL-1beta and

116 Moreover, the gene upregulation of proangiogenic factors induced by the pathological proces

117 , and decreased expression of HIF-1alpha and proangiogenic factors NF-kappaB and VEGFR2 in the 7-d fi

118 nding, correlating with diminished levels of proangiogenic factors PGE(2) and VEGF in cutaneous wound

119 ificantly increased CSC survival in hypoxia, proangiogenic factors production and endothelial differe

120 progression(5,6); however, neutralization of proangiogenic factors such as vascular endothelial growt

121 ist because of the local production of other proangiogenic factors that may cause resistance to anti-

122 the following 2 mechanisms: (1) secretion of proangiogenic factors that stimulate endogenous neovascu

123 ting polypeptides form a balance of anti and proangiogenic factors tightly regulated by proteolysis.

124 sfully applied using various combinations of proangiogenic factors together with a biodegradable deli

125 did not increase the secretion of the common proangiogenic factors VEGF and basic fibroblast growth f

126 and their downstream targets, including the proangiogenic factors VEGF and PDGF.

127 in significantly increased secretion of the proangiogenic factors VEGF and platelet-derived growth f

128 al NK (dNK) cells lack cytotoxicity, secrete proangiogenic factors, and regulate trophoblast invasion

129 precise regulation of hypoxia-inducible and proangiogenic factors, and that amacrine and horizontal

130 ed by hypoxia-driven residual VEGF and other proangiogenic factors, combinations of agents from these

131 t miR-184 directly targets and represses the proangiogenic factors, friend of Gata 2 (FOG2), platelet

132 is was associated with a global reduction of proangiogenic factors, including insulin-like growth fac

133 dition, we found that Gli3 regulates several proangiogenic factors, including thymidine phosphorylase

134 ced the autocrine expression of two relevant proangiogenic factors, vascular endothelial growth facto

135 0 with antiangiogenic antibodies targeting 2 proangiogenic factors, vascular endothelial growth facto

136 oing so, maintains the pool of nerve-derived proangiogenic factors.

137 regulated by a complex interplay of anti and proangiogenic factors.

138 STAT5A regulates the secretion of autocrine proangiogenic factors.

139 xic stress and the production of detrimental proangiogenic factors.

140 is a known mitogen, and both FGF2/MMP-9 are proangiogenic factors.

141 the responsiveness of ischemic myocardium to proangiogenic factors.

142 cells also exhibited prolonged elevation of proangiogenic factors.

143 ogenesis by augmenting expression of several proangiogenic factors/genes.

144 administered CgA was cleaved in favor of the proangiogenic form and was associated with increased mic

145 FABP4 exhibits a proangiogenic function in vitro, but whether it plays a

146 in for Clathrin, is essential to mediate the proangiogenic function of BMP2 signaling.

147 de a molecular basis for a context-dependent proangiogenic function of BMP2 signaling.

148 chemokines to attract monocytes and activate proangiogenic function of macrophages in the tumor micro

149 A proangiogenic function of tissue-infiltrating monocytes/

150 etion of myeloid-derived KDR compromised its proangiogenic function, which inhibited the angiogenic s

151 tivation of VEGF expression and promotes its proangiogenic function.

152 xpanding its role in cancer beyond its known proangiogenic function.

153 We conclude that CYTL1 can mediate proangiogenic functions ascribed to endothelial progenit

154 Here, we show that Gal-1 exhibits proangiogenic functions during early stages of pregnancy

155 Pharmacological targeting of MSCs proangiogenic functions may prevent their contribution t

156 Unlike well-characterized proangiogenic functions of endothelial cell Nrp1, the co

157 hat alpha9beta1 cross-suppresses alpha3beta1 proangiogenic functions.

158 Hydrogen sulfide is a vasorelaxant and proangiogenic gas with therapeutic potential in several

159 ed anti-inflammatory, immunosuppressive, and proangiogenic gene products compared with macrophages fr

160 giogenesis by upregulating the expression of proangiogenic genes and by activating pathways that prom

161 Furthermore, roIFNT stimulated proangiogenic genes, including FGF2, PDGFB, and PDGFAR.

162 ted with aPL-positive IgG expressed multiple proangiogenic genes, including vascular endothelial grow

163 Endothelial Growth Factor (VEGF)-dependent, proangiogenic GIPC1-Neuropilin 1 complex, recasting GIPC

164 lial growth factor (VEGF)-A levels, a potent proangiogenic growth factor to induce angiogenesis, and

165 FCSCs produced an abundance of the proangiogenic growth factor vascular endothelial growth

166 ompanied by suppressed circulating levels of proangiogenic growth factors (EGF [epidermal growth fact

167 Proangiogenic growth factors (GFs) stimulate cell prolif

168 angiogenic switch via paracrine secretion of proangiogenic growth factors and by direct luminal incor

169 Q in hydrogels formed spheroids and secreted proangiogenic growth factors that significantly increase

170 motes cell proliferation and survival and is proangiogenic, implicating it as a contributor to virus-

171 In vitro, NaHS was proangiogenic in an endothelial tube assay and attenuate

172 ndothelial gene transcription, positively of proangiogenic KDR and negatively, in part, of antiangiog

173 leading to accumulation of inflammatory and proangiogenic low molecular weight hyaluronan fragments.

174 asL) preferentially induces the migration of proangiogenic M2 macrophages into the laser lesions and

175 cytokine production in aged macrophages and proangiogenic M2 macrophages.

176 s and hypermethylation of anti-inflammatory, proangiogenic M2-Mvarphi genes in hyperlipidemia and T2D

177 varphis, compared with anti-inflammatory and proangiogenic M2-Mvarphis in hyperlipidemia and T2DM isc

178 emical screen to identify drugs that inhibit proangiogenic M2-type macrophage polarization and block

179 Proangiogenic M2-type macrophages promote various pathol

180 s in various conditions that are promoted by proangiogenic M2-type macrophages, including neovascular

181 t the polarization of macrophages toward the proangiogenic M2-type.

182 sed with endothelial cells and expressed the proangiogenic marker TIE2.

183 n increased upregulation of inflammatory and proangiogenic markers.

184 dramatically reduced ability to release the proangiogenic mediator vascular endothelial growth facto

185 ivation promoted upregulation of a number of proangiogenic mediators (VEGF, FGF-2, IL-6, etc.) and do

186 at promotes secretion of proinflammatory and proangiogenic mediators as part of a unique senescence p

187 Primary antibodies against inflammatory and proangiogenic mediators such as RAGE, GFAP, 5-LO, VEGF a

188 associated with enhanced phosphorylation of proangiogenic mediators VEGF receptor 2 and endothelial

189 protein levels with concomitant increases in proangiogenic mediators.

190 secretion from human CD34(+) cells contains proangiogenic, membrane-bound nanovesicles called exosom

191 ygenase (COX) and cytochrome P450 to produce proangiogenic metabolites.

192 We further show that the proangiogenic microfibrillar-associated protein 5 (MFAP5

193 ce in mice and humans, resulting in a novel, proangiogenic microRNA with a unique targetome.

194 argeted nanoparticle transfection to deliver proangiogenic microRNA-132 (miR-132) to cultured ECs bef

195 tumors demonstrated increased expression of proangiogenic MIP-2 (CXCL2) ex vivo.

196 sized that miR-126, an endothelial-specific, proangiogenic miR, is down-regulated in the peripheral m

197 Specifically, proangiogenic miR-126 was regulated by GATA2 transcripti

198 Nanoparticle-mediated delivery of proangiogenic miR-126 was tested in the reendothelializa

199 ssion of miR-221 was mediated through direct proangiogenic miR-221 target genes ICAM1 and ETS1.

200 Exosome-shuttled proangiogenic miRNAs may signify amplification of stem c

201 CD34Exo were found to be enriched with proangiogenic miRNAs such as miR-126-3p.

202 d for IL-17 receptor A, and for protumor and proangiogenic molecular mediators, which were up-regulat

203 vascular endothelial growth factor (a potent proangiogenic molecule), display reduced cytotoxicity, a

204 tal skin did not reveal the expected bent to proangiogenic molecules, indicating a complex regulation

205 /macrophages (TEMs) are a distinct subset of proangiogenic monocytes selectively recruited to tumors

206 ischemia, MAPCs stimulate the recruitment of proangiogenic monocytes through endothelial activation a

207 ery of blood flow through the recruitment of proangiogenic monocytes.

208 These proangiogenic MPs were selectively recruited to sites of

209 led to downregulation of KDR, suppression of proangiogenic myeloid cells, and prevention of low-grade

210 angiogenic switch through the positioning of proangiogenic neutrophils in proximity to Cyp46a1(+) isl

211 ession profiles of cytokines contributing to proangiogenic paracrine effects.

212 20(+) lymphocytes, which in turn initiates a proangiogenic pathway leading to enhanced angiogenesis a

213 Mdm2 phosphorylation on Ser(166) is a novel proangiogenic pathway within the skeletal muscle.

214 has been identified as a new CXCL2-dependent proangiogenic pathway.

215 rognosis, but attempts to target established proangiogenic pathways within the vascular niche have be

216 e capacity to rapidly upregulate alternative proangiogenic pathways, increased invasive capacity, and

217 487b targetome that is enriched for multiple proangiogenic pathways.

218 d colleagues reported that expression of the proangiogenic peptide apelin (APLN) was decreased and GB

219 tion surrounding cells in the microgels, the proangiogenic phenotype of hMSCs can be tuned in a contr

220 affolds with thicker fibers exhibited a more proangiogenic phenotype that promoted endothelial sprout

221 on and blunted in vivo signaling through the proangiogenic phosphoinositide-3-kinase/Akt/eNOS cascade

222 luble fms-like tyrosine kinase 1 (sFlt1) and proangiogenic placental growth factor (PlGF) at presenta

223 encing the mobilization and recruitment of a proangiogenic population of bone marrow-derived myeloid

224 simultaneously increased the osteogenic and proangiogenic potential of entrapped cocultured cells.

225 The proangiogenic potential of genetically engineered mesenc

226 essing tumors exhibited relatively increased proangiogenic potential, suggesting that prostate tumor-

227 simultaneously promote their osteogenic and proangiogenic potential.

228 ith endothelial phenotype and enhanced their proangiogenic potential.

229 echanisms that blunted endothelial IL-25 and proangiogenic progenitor cell thymic stromal lymphopoiet

230 c asthma model, whereas adoptive transfer of proangiogenic progenitor cells from wild-type mice in an

231 We hypothesized that bone marrow-derived proangiogenic progenitor cells that contain eotaxins con

232 endothelial TGF-beta signals favors Smad1/5 proangiogenic programs and dictates increased angiogenic

233 Here, we show that the proangiogenic, proinflammatory cytokine CXCL7 is an inde

234 demonstrating impaired in vitro and in vivo proangiogenic properties (proliferation, migration, tube

235 ess immunoregulatory, anti-inflammatory, and proangiogenic properties and, therefore, have the potent

236 like growth factor signaling may mediate the proangiogenic properties of embryonic-derived macrophage

237 me pair, predetermines immunosuppressive and proangiogenic properties of myeloid cells.

238 The IGFBP-vWC form has potent proangiogenic properties promoting retinal endothelial c

239 s of CD34(+) PBMCs, associated with impaired proangiogenic properties that could be rescued by miR-mi

240 20-HETE is known to have prohypertensive and proangiogenic properties, the effects of CYP4F-derived m

241 e 3 (Olfml3) is a matricellular protein with proangiogenic properties.

242 MC subsets and their relevance for different proangiogenic properties.

243 rowth of certain neoplasias because of their proangiogenic properties.

244 y analysis revealed attenuated expression of proangiogenic proteins in ischemic AMPKalpha2(DeltaMC) h

245 paB and calpain-2 and secreted levels of the proangiogenic proteins intercellular adhesion molecule-1

246 showed significant decrease in the levels of proangiogenic proteins versus nonspecific control-transf

247 sis by regulating the expression of secreted proangiogenic proteins.

248 ate from these platelets contained decreased proangiogenic proteins.

249 ts tumour cells to elevate expression of the proangiogenic/protumourigenic transmembrane receptor Tis

250 sion.Significance: This study highlights the proangiogenic receptor neuropilin 1 in macrophages and m

251 barrier formation (EV-miR-21/126) or exert a proangiogenic response (HDL-miR-132).

252 re sCD146 binds to angiomotin to stimulate a proangiogenic response.

253 aken together, these results reveal a novel, proangiogenic role of fibulin-3 in gliomas, highlighting

254 Consistent with a proangiogenic role, gammadelta T cells promoted the form

255 Consistent with proangiogenic roles for alpha3beta1, alpha3-null keratin

256 activated Src, which in turn phosphorylated proangiogenic RTKs, including platelet-derived growth fa

257 Angiogenin (ANG) is a 14-kDa multifunctional proangiogenic secreted protein whose expression level co

258 igration of endothelial cells (ECs) toward a proangiogenic signal.

259 f mTOR, substantially amplifying the initial proangiogenic signal.

260 ds that induce a sustained inhibition of the proangiogenic signaling generated by tumor hypoxia still

261 ts demonstrate that GRM1 activation triggers proangiogenic signaling in melanoma, offering a mechanis

262 in that has also been found to function as a proangiogenic signaling molecule.

263 cape antiangiogenic therapy by activation of proangiogenic signaling pathways.

264 sh whether blue light filtering could modify proangiogenic signaling produced by retinal pigmented ep

265 w antiangiogenic compound (22) that inhibits proangiogenic signaling under hypoxic conditions in brea

266 ing the strong adhesion that is required for proangiogenic signaling via these integrins.

267 ed H-Ras in mediating nitric oxide-dependent proangiogenic signaling.

268 However, the molecular links between proangiogenic signals and downstream gene expression rem

269 ken together, these results demonstrate that proangiogenic signals converge to enhance expression and

270 te a prominent role for SOX11 as a driver of proangiogenic signals in MCL, and highlight the SOX11-PD

271 dothelial cell (EC) activation and changed a proangiogenic signature.

272 tein, can activate latent antiangiogenic and proangiogenic sites, respectively.

273 ithin the tumor microenvironment and produce proangiogenic soluble factors.

274 Turning this switch toward a proangiogenic state involves an altered interplay betwee

275 tissues, ECs divide and migrate rapidly upon proangiogenic stimulation.

276 Despite increasing its gene occupancy, proangiogenic stimuli decrease ERRalpha expression in EC

277 Proangiogenic stimuli induce ILF3 mRNA and protein expre

278 bed and counterintuitive prohypoxia role for proangiogenic TEMs in breast cancer which is, in part, s

279 Reduced numbers of proangiogenic TEMs in macrophage HIF-1alpha-deficient tu

280 Proangiogenic TEMs in macrophage HIF-2alpha-deficient tu

281 There is an unmet need for proangiogenic therapeutic molecules for the treatment of

282 TR3/Nur77 is a potential candidate for proangiogenic therapy.

283 This sharp switch from proangiogenic to antiangiogenic effect of TNF observed w

284 es: To test whether nanoparticle delivery of proangiogenic transcription factor FOXM1 (forkhead box M

285 Delivery of proangiogenic transcription factors has promise as a the

286 of the TSP-1 promoter repressed by NR4A2 and proangiogenic transcription factors, including NF-kappaB

287 Proangiogenic transcripts containing adenine and uridine

288 ILF3 stabilizes proangiogenic transcripts including VEGF, CXCL1, and IL-

289 ugh cytokine-inducible mRNA stabilization of proangiogenic transcripts.

290 progenitor cells (EPCs) and plasma levels of proangiogenic vascular endothelial growth factor and of

291 ntal growth factor (PlGF) is a member of the proangiogenic vascular endothelial growth factor family,

292 nly by cystathionine gamma-lyase (CSE), is a proangiogenic vasodilator.

293 gulation through selective downregulation of proangiogenic VEGF isoforms (via SRPK1 inhibition) or co

294 n 8-encoded residues, which are found in all proangiogenic VEGF-A isoforms, in Nrp binding.

295 The proangiogenic VEGF-A165a isoform is neuroprotective in h

296 d a corresponding reduction in levels of the proangiogenic VEGF-A165a splice isoform.

297 p-regulation of prooxidant NADPH oxidase and proangiogenic VEGF.

298 SRPIN340 reduced the expression of proangiogenic VEGF165 without affecting VEGF165b express

299 wth factor (VEGF)-A results in production of proangiogenic VEGFxxxa isoforms (VEGF165a, 165 for the 1

300 gel assay, we showed that ct-8,9-E-11-HET is proangiogenic, whereas ct-8,9-E-15-HET is not active.